Zotatifin
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex[1]. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM) [2]. Zotatifin induces cell apoptosis[1].
Product Specifications
CAS Number
2098191-53-6
Product Name Alternative
EFT226
UNSPSC
12352005
Target
Apoptosis; Eukaryotic Initiation Factor (eIF) ; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/zotatifin.html
Concentration
10mM
Purity
99.69
Solubility
DMSO : ≥ 100 mg/mL
Smiles
N#CC1=CC=C([C@@]2(O3)[C@@](C4=C3C=C(OC)N=C4OC)(O)[C@H](O)[C@H](CN(C)C)[C@H]2C5=CC=CC=C5)C=C1
Molecular Formula
C28H29N3O5
Molecular Weight
487.55
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
EIF4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Pmel17 / gp100 / SILV (NKI-beteb), CF740 conjugate, 0.1mg/mL
CD106 / VCAM1 (1.4C3), CF568 conjugate, 0.1mg/mL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF640R conjugate, 0.1mg/mL
